CD34 and leukemia: Interestingly, we consistently observed a greater fraction of Sca1+CD34+ cells in DKO relative to E2f1+2+ leukemias (Figure 4C), consistent with the early advantage provided by Bcr-Abl expression in DKO progenitor-enriched populations (Figure 2C).